Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 7241Neoplasms 4538Prostatic Neoplasms 3489Colorectal Neoplasms 2939Carcinoma, Non-Small-Cell Lung 2829Lung Neoplasms 2546Leukemia, Myeloid, Acute 1982Pancreatic Neoplasms 1873Multiple Myeloma 1810Carcinoma, Hepatocellular 1732Neoplasm Metastasis 1585Stomach Neoplasms 1501Lymphoma 1456Precursor Cell Lymphoblastic Leukemia-Lymphoma 1435Head and Neck Neoplasms 1434Brain Neoplasms 1370Melanoma 1346Ovarian Neoplasms 1342Leukemia 1303Rectal Neoplasms 1270Recurrence 1254Colonic Neoplasms 1204Glioblastoma 1137Uterine Cervical Neoplasms 1096Lymphoma, Non-Hodgkin 1065Leukemia, Lymphocytic, Chronic, B-Cell 989Esophageal Neoplasms 965Lymphoma, Follicular 936Lymphoma, Large B-Cell, Diffuse 932Squamous Cell Carcinoma of Head and Neck 921

Interventions

tislelizumab 1lenvatinib 1gemcitabine-oxaliplatin regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Interventional × Potentially Resectable Locally Advanced Malignant Tumors of Biliary System × Clear all
NCT05036798 2022-09-07

Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
30 enrolled
Gastrointestinal

Potentially Resectable Locally Advanced Malignant Tumors of Biliary System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡